Oleh Zagrijtschuk

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera

Heinz Gisslinger, Oleh Zagrijtschuk, Veronika Buxhofer‐Ausch et al. · Blood · 2015 · 176 citations · Full text

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg‐proline‐interferon alpha‐2b

Nicole C.C. Them, Klaudia Bagienski, Tiina Berg et al. · American Journal of Hematology · 2014 · 53 citations · Full text

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

C. Pecquet, Nicolas Papadopoulos, Thomas Balligand et al. · Blood · 2022 · 43 citations · Full text

Pathology, Molecular Biology, Cytoskeleton +20

SURPASS-ET: phase III Study of Ropeginterferon Alfa-2b versus Anagrelide as Second-Line Therapy in Essential Thrombocythemia

Srđan Verstovšek, Norio Komatsu, Harinder Gill et al. · Future Oncology · 2022 · 38 citations · Full text

Essential Thrombocythemia, High-risk Essential Thrombocythemia, Immunology +17

Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study

Yoko Edahiro, Kohshi Ohishi, Akihiko Gotoh et al. · International Journal of Hematology · 2022 · 34 citations

Polycythemia Vera, Ropeginterferon Alfa-2b, Hematology +3